Entero Healthcare Solutions has successfully closed its acquisition of a 51.5% stake in Anand Chemiceutics Private Limited, a leading distributor of diagnostic and MedTech products. This strategic move is expected to boost Entero’s annualized revenue contribution from the MedTech segment to over ~INR 1,000 Cr in the next financial year. The deal leverages Anand Chemiceutics’ deep expertise and pan-India presence to enhance Entero’s integrated healthcare supply chain capabilities.
Entero Finalizes Major Stake Acquisition
On Monday, 09th February 2026, Entero Healthcare Solutions Limited announced the successful closing of its acquisition of 51.5% stake in Anand Chemiceutics Private Limited. This move marks a significant step in Entero’s strategy to become a comprehensive healthcare supply chain provider, building upon the initial acquisition announcement made on November 12, 2025.
Strategic Rationale and Synergy
Anand Chemiceutics is recognized as an industry leader in distributing diagnostic products and serves as a preferred channel partner for global MedTech companies. The acquired entity possesses over two decades of trust and technical expertise, boasting a customer network exceeding 1,500 laboratories, hospitals and government institutions across India. This acquisition is highlighted for its potential to:
- Scale Entero’s presence in the large and high-growth MedTech market.
- Leverage collective distribution strength, geographical reach, and expertise.
- Accelerate the vision for an integrated healthcare supply chain solution.
Leadership Commentary
Mr. Prabhat Agrawal, MD and CEO of Entero Healthcare, stated that the partnership strategically positions the combined entity to build scale in this attractive segment by merging Anand Chemiceutics’ track record with Entero’s distribution capabilities.
Mr. Jayesh Sancheti, MD of Anand Chemiceutics, described the integration as creating a “powerhouse”, merging Anand Chemiceutics’ legacy trust in diagnostics with Entero’s scale and technology to create a meaningful difference in patient lifecycles.
Projected Financial Impact
Following the completion of this transaction, the MedTech segment within Entero Healthcare is anticipated to contribute more than ~INR 1,000 Cr in annualized revenue in the upcoming financial year.
About the Acquired Entity
Established in 2003, Anand Chemiceutics Private Limited specializes in delivering advanced diagnostics, medical devices, and end-to-end turnkey solutions. Headquartered in Pune, the company offers strong regional presence in Mumbai, Gurugram, and Bengaluru, combining nationwide reach with on-ground execution excellence.
Source: BSE
